Application of a DSS colitis model in toxicologically assessing norisoboldine

Abstract

In standard nonclinical drug safety evaluation studies, limitations exist in predicting the clinical risk of a drug based only on data from healthy animals. To obtain more comprehensive toxicological information on norisoboldine (NOR), we conducted an exploratory study using C57BL/6 mice in addition to healthy mice as models of dextran sodium sulfate (DSS) colitis to evaluate the safety of NOR. The healthy mice and DSS colitis mice were exposed to 30 or 90 mg NOR/kg body weight or water for 15 days. Compared with the model control group, 90 mg/kg of NOR aggravated the symptoms and colonic lesions of the DSS colitis mice and even caused death in two animals. No significant adverse effects were observed in the healthy mice. These different toxic reactions to NOR in the healthy and DSS colitis mice indicate that NOR toxicity varies by status among animals and suggests that the DSS colitis mouse model may be more susceptible, accurate and comprehensive in evaluating the safety of NOR. In conclusion, 90 mg/kg of NOR may be safe for healthy mice but not for DSS colitis mice. The DSS colitis mouse model, with many features similar to those of human colitis patients, may be a novel choice to counteract the deficiencies of using healthy mice to evaluate the safety of anti-inflammatory bowel disease (IBD) drugs, and further research is required.

Keywords:

• DSS colitis mouse model
• safety evaluation
• norisoboldine
• programed cell death

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Natural Science Foundation of Zhejiang province [under Grant LQ19H280009, LQ18H280003]; Special Projects of Zhejiang Academy of Medical Sciences [under Grant CA1918D-04]; Safety Research and Evaluation Center Subject of Zhejiang Academy of Medical Sciences [under Grant ZA1703S]; Science and Technology Project of Zhejiang Provincial Administration of Traditional Chinese Medicine [under Grant 2019ZB034]; Natural Science Foundation of Zhejiang Chinese Medical University [under Grant 2018ZG28]; Science and Technology Project of Zhejiang Province [under Grant 2018C37127].